19th week of 2009 patent applcation highlights part 35 |
Patent application number | Title | Published |
20090116992 | Method for making Mg-based intermetallic compound - A method for making Mg(magnesium)-based intermetallic compound uses a thermal process during a melting process to produce largely the Mg-based intermetallic compound. The vapor pressure of Mg is high, thereby Mg is prone to be vaporized from a melt and a wrought solid alloy in the melting process of high temperature, for purifying the wrought Mg-based intermetallic compound. The method may simplify the process and devices for making the Mg-based intermetallic compound, and produce efficiently a larger of high purity Mg-based intermetallic compound. | 2009-05-07 |
20090116993 | AE SERIES HEAT RESISTANT COMPRESSION CASTING MAGNESIUM ALLOY CONTAINING CERIUM AND LANTHANUM - This invention relates to an AE series heat resistant compression casting magnesium alloy containing cerium and lanthanum and the composition ingredients and the weight percentage thereof are as follows: Al: 3%˜5%, Ce: 0.4%˜2.6%, La: 0.4%˜2.6%, Mn: 0.2%˜0.6%, and the remainder is magnesium. The raw material of cerium lanthanum mixture of rare earth used is the residual, cheap and overstocked cerium lanthanum mixture of rare earth obtained from common cerium rich mixture of rare earth after the Nd, Rr with high value and good market have been separated. The mechanical performance of this invention at room temperature and high temperature excels that of AE 44 and AZ 91 alloys, and the minimum creep rate of 1.82×10-9 S-1 and the creep percentage elongation in 100 h of 0.17% at the condition of 200° C. and 70 MPa excel these of AE 44 alloy. | 2009-05-07 |
20090116994 | High ductility/strength magnesium alloys - A magnesium alloy comprising up to about six weight percent zinc and up to about one weight percent cerium may be hot worked to produce an intermediate or final alloy workpiece that exhibits enhanced ductility and strength at room temperature. The addition of zinc and a small amount of cerium may affect the magnesium alloy by increasing strength and ductility, and improving the work hardening behavior. | 2009-05-07 |
20090116995 | DENSIFIED MOLYBDENUM METAL POWDER - Densified molybdenum metal powder. Densified molybdenum metal powder has substantially generally spherical particles, surface-area-to-mass ratio of no more than about 0.5 m | 2009-05-07 |
20090116996 | COPPER ALLOY, COPPER ALLOY PLATE, AND PROCESS FOR PRODUCING THE SAME - A copper alloy with an excellent stress relaxation resistance including Ni: 0.1 through 3.0 mass %, Sn: 0.01 through 3.0 mass %, P: 0.01 through 0.3 mass % and remainder copper and inevitable impurities, and the Ni content in extracted residues separated and left on a filter having filter mesh size of 0.1 μm by using an extracted residues method accounting for 40 mass % or less of the Ni content in the copper alloy, wherein the extracted residues method requires that 10 g of the copper alloy is immersed in 300 ml of a methanol solution which contains 10 mass % of ammonium acetate, and using the copper alloy as the anode and platinum as the cathode, constant-current electrolysis is performed at the current density of 10 mA/cm | 2009-05-07 |
20090116997 | COPPER ALLOY TUBE FOR HEAT EXCHANGERS - A copper alloy tube according to the present invention includes Sn 0.1 to 2.0 mass %, P 0.005 to 0.1 mass %, S 0.005 mass % or less, O 0.005 mass % or less, and H 0.0002 mass % or less, and the remainder has a composition consisting of Cu and unavoidable impurities. And, as is annealed, the copper alloy tube has the following characteristics: a tensile strength in the longitudinal direction of the copper alloy tube is 250 N/mm | 2009-05-07 |
20090116998 | HIGHLY CRYSTALLINE SILVER POWDER AND PRODUCTION METHOD OF HIGHLY CRYSTALLINE SILVER POWDER - Object of the present invention is to provide a production method of a highly crystalline silver powder containing powder particles in fine particle region and having a good particle size distribution as well as the highly crystalline silver powder obtained by the production method. In order to achieve the object, the present invention adopts a production method characterized in that the method comprises preparation of a first aqueous solution in which gelatin, silver nitrate and nitric acid are dissolved in water, preparation of a second aqueous solution in which L-sorbic acid and/or ascorbic acid and a water-soluble organic acid are dissolved, adding of the second aqueous solution slowly to mix with the first aqueous solution, stirring of the mixture to grow the silver particles after finishing the mixing, keeping of the mixture still to settle the silver particles, discarding of the supernatant, filtration and rinsing to obtain the highly crystalline silver powder. | 2009-05-07 |
20090116999 | Aluminium Alloy With Improved Crush Properties - An Al—Mg—Si alloy with improved ductility and crush properties, in particular useful for structural components in crash exposed areas in vehicles. The alloy contains in wt %: Mg 0.25-1.2; Si 0.3-1.4; Ti 0.03-0.4, where Ti is present in solid solution and where the alloy contains in addition one or more of the following alloy components: Mn max 0.6; Cr max 0.3; Zr max 0.25, and incidental impurities, including Ee and Zn up to 0.5 with balance Al. | 2009-05-07 |
20090117000 | Air Sterilization Apparatus - An air sterilization apparatus for sterilizing air that can include a fan assembly, which may be mounted in an upper-part of a room, and a UVC lamp to emit a UVGI field. The air sterilization apparatus may direct air across the UVGI field to sterilize the air. A baffle may also be provided to shield the eyes of occupants of the room from UVC energy contained in the UVGI field. The air sterilization apparatus may also include an illuminator lamp to provide illumination to a room. | 2009-05-07 |
20090117001 | Event-triggered ultraviolet light sterilization of surfaces - Solutions for limiting the undesirable spread of pathogens by indirect contact are provided. The solutions involve event-controlled self-sterilization of contact regions on articles or fixtures. A self-sterilizing article structure, in response to a contact event, allows sterilizing UV energy to controllably flow from a UV generator within the article to a portion of the contact region. | 2009-05-07 |
20090117002 | NANOPARTICLE ASSEMBLIES WITH MOLECULAR SPRINGS - A nanoscale sensing device from different types of nanoparticles (NPs) and nanowires (NWs) connected by molecular springs. The distance between the nanoscale colloids reversibly changes depending on conditions or analyte concentration and can be evaluated by fluorescence measurements. | 2009-05-07 |
20090117003 | LIQUID DELIVERY APPARATUS - Provided is a pipette head assembly and tip holder apparatus for use in an automated liquid handling device, which apparatus comprises a pipette head assembly mountable in the device and a pipette tip holder comprising locations for holding pipette tips for the pipette head assembly;
| 2009-05-07 |
20090117004 | SYSTEM FOR AUTOMATICALLY LOADING IMMUNOASSAY ANALYZER - A component of a laboratory automation system that integrates (a) separating a solid magnetic substrate from the liquid contents of a reaction vessel, (b) management of the thermal characteristics of the component of the laboratory automation system, (c) automated loading of multi-well plates and tip combs into the component of the laboratory automation system, (d) automated unloading of multi-well plates and tip combs from the component of the laboratory automation system, and (e) reading of radio frequency identification tags attached to multi-well plates. | 2009-05-07 |
20090117005 | Unit Cuvette for Analyzing a Biological Fluid, Automatic Device for In Vitro Analysis - The bottom of the cuvette comprises a curved raceway placed so as to guide the oscillating movement of a ball inserted into the cuvette. In addition, the cuvette comprises means of attachment, in two perpendicular directions, to adjacent unit cuvettes. The cuvettes can thus be stored as plates in a feed magazine of an analytical device. The analytical device comprises several stations placed around a rotary ring. Only where it is desired to determine the clotting time of the blood contained in the cuvette a ball is introduced into the latter, at a ball distribution post. The cuvette equipped in this way is then brought to a station where the test is carried out. The major advantage of the invention is the polyvalence of the cuvette and of the analytical device. | 2009-05-07 |
20090117006 | STRUCTURES FOR ENHANCED DETECTION OF FLUORESCENCE - Substrates are provided for use in the detection, identification and analysis of biologic or chemical samples that are labeled with a fluorescent label, in which the plane of maximum fluorescence is displaced from a reflective substrate surface so that the intensity maximum of the standing wave interference pattern of incident and reflected probe radiation is enhanced. The format of the substrates includes substantially planar surfaces as well as substrates with introduced variations to the substrate surface, e.g., depressions, wells, pedestals and the like, disposed in arrays or other similar structures such that one or more fluorophore-comprising objects can be attached thereto. | 2009-05-07 |
20090117007 | GAS SENSOR - A gas sensor including a detection element having a stacked structure configured to detect a specified gas component contained in a gas to be detected. The detection element includes: a sensing portion including one or more solid electrolyte layers containing a first material as a main component and having a first surface and a second surface opposite the first surface; a first portion stacked on the first surface and including one or more first base layers containing a second material as a main component different from the first material; and a second portion stacked on the second surface and including one or more second base layers containing the second material. A total thickness of the one or more second base layers in a stacking direction is not less than 80% but not more than 120% of a total thickness of the one or more first base layers. | 2009-05-07 |
20090117008 | Two-phase pipette - The invention relates to a two-phase electronic pipette, in which the piston can be moved from the basic position to the lower position and in which the distance between basic position and lower position can be changed. | 2009-05-07 |
20090117009 | MULTI-CHANNEL ELECTRONIC PIPETTOR - A multi-channel electronic pipettor has a removable lower multi-channel assembly to facilitate autoclaving. The pipettor includes a position holding mechanism which allows adjustment of the angular position of the lower multi-channel assembly with respect to the handle assembly. The lower multi-channel assembly includes a cylinder block including a plurality of aspiration cylinders along with a plurality of pistons, a series of pipette tip mounting shafts and a manifold to communicate between the aspiration cylinders and the air passageways in the pipette tip mounting shafts, among other components. The volume of the air passageways in the manifold is balanced among channels to improve tip-to-tip pipetting accuracy. In addition, the lower multi-channel assembly includes an internal frame to which the other components, such as a cylinder block, are attached either directly or indirectly. | 2009-05-07 |
20090117010 | PIPETTING APPARATUS WITH INTEGRATED LIQUID LEVEL AND/OR GAS BUBBLE DETECTION - A pipetting apparatus has a fluidic space to which a pressure transducer with a pressure sensor is attached with a gas filled space. The fluidic space is defined by a pipette tip, a first tubing that connects the pipette tip to a pump, and an active part of the pump. The pipetting apparatus further has an impulse generating mechanism that is in operative contact with a column of system liquid inside the fluidic space. The impulse generating mechanism induces a vertical movement in the system liquid column, which results in a pressure variation in the gas filled space that is pneumatically connected with the fluidic space. This pressure variation, as recorded with the pressure transducer and as processed by a first data processing unit during utilization of this pipetting apparatus, is taken as an indicator for the detection of penetration or of quitting of a surface of a liquid, with an orifice of the pipette tip, of which liquid an amount is to be aspirated and dispensed. This pressure variation is also taken as an indicator for the detection of the presence or the absence of gas bubbles in the system liquid contained in the fluidic space of this pipetting apparatus. | 2009-05-07 |
20090117011 | CARRIER FRAME AND METHOD - A sample storage system and method for transporting a medium containing a biological sample. In one aspect the system includes a generally U-shaped carrier frame adapted to facilitate the insertion of a sampling medium into the carrier. The carrier may be configured for use with an automated sampling and storage system. | 2009-05-07 |
20090117012 | Air Treatment Device Utilizing A Sensor For Activation And Operation - The present invention provides a system for detecting a malodor and dispensing an air treatment when needed. In an exemplary embodiment of the present invention, the system includes a selection mechanism which allows the user to choose how the system dispenses the air treatment, a sensor, a timing control circuit coupled with the sensor, and a delivery system coupled with the timing control circuit. Upon detection of a malodor by the sensor, the sensor communicates with the timing control circuit which, in turn, communicates with the delivery system to dispense the air treatment. In another exemplary embodiment of the present invention, an air-freshening system is shown that combines a continuous dispensing system with a sensing dispensing system. | 2009-05-07 |
20090117013 | PROCESS FOR CONTINUOUS PREPARATION OF HIGH MOLECULAR WEIGHT POLYESTERS BY ESTERIFICATION OF DICARBOXYLIC ACIDS AND/OR TRANSESTERIFICATION OF DICARBOXYLIC ACIDS WITH DIOLS AND/OR MIXTURES THEREOF AND AN APPARATUS THEREFOR - The present invention relates to a method for the continuous production of high-molecular polyesters by esterification of dicarboxylic acids and/or transesterification of dicarboxylic acid esters with diols and/or mixtures thereof in the presence of catalysts with formation of a prepolymer in a tower reactor and polycondensation thereof to form a high-molecular polyester in a polycondensation reactor, a prepolymer with >40 to 70 repeat units (DP) being produced in the tower reactor and this prepolymer being polycondensed in only one further reactor to form a polyester with >150 to 205 DP. | 2009-05-07 |
20090117014 | SYSTEM AND METHOD FOR AMMONIA SYNTHESIS - Systems and methods are disclosed herein for synthesizing ammonia at mid- to low-pressures using nano-size metal or metal alloy catalyst particles. Hydrogen and nitrogen gases are passed through a system comprising, for example, a packed bed of supported nano-size iron or iron alloy catalyst particles having an optional oxide layer that form the catalyst. | 2009-05-07 |
20090117015 | LIQUEFYING APPARATUS - A conversion-to-oil apparatus capable of efficiently treating plastic, includes a melting unit for heating and melting plastic fed thereto and a decomposing unit for further heating and vaporization-decomposing the molten plastic melted by the melting unit, wherein the decomposing unit is inclined upwardly, having a lead screw mounted therein, and is provided at its upper end portion with a catalyst cylinder extending upwardly and a residue takeout unit extending downwardly, and the decomposing unit has a prevention element for preventing molten plastic gas from flowing down to the residue takeout unit. | 2009-05-07 |
20090117016 | FUMIGATION AND SANITATION OF BIOLOGICAL PRODUCTS STORAGE SYSTEMS USING OZONE - An apparatus and method are provided for elimination of mold, pests, insects and the like from bulk, stored grain and milled grain products and other biological items by pushing an ozone-containing atmosphere up through the grain or biological items and providing and maintaining an ozone-containing atmosphere in contact with the upper surface of the grain or biological items and maintaining an ozone-containing atmosphere in the spaces of the storage contained that are below the grain or biological items. | 2009-05-07 |
20090117017 | CATALYTIC CONVERSION APPARATUS - The present invention relates to a catalytic conversion apparatus, characterized in that said apparatus comprises at least one feed oil cracking riser reactor, a dense bed reactor, a disengager, and a stripper, wherein said stripper locates below said dense bed reactor and communicates directly with the lower part of the dense bed reactor or through a fluid-communicating channel, the outlet of at least one of said riser reactor(s) communicates with the lower part of said dense bed reactor or any part of said fluid-communicating channel, the outlet of said dense bed reactor communicates with the inlet of a gas-solid separating apparatus located in said disengager through said disengager and/or through an optional transporting channel, the catalyst outlet of said disengager communicates with at least one position selected from the upper part of said stripper, any part of said fluid-communicating channel, and the lower part of said dense bed reactor, through at least one catalyst transporting channel. The catalytic conversion apparatus according to the present invention sets up at least one riser reactor and a dense bed reactor to carry out further cracking of the intermediate products, produced from the feed oil by the cracking reaction in the riser, in the dense bed reactor. Moreover, the spent catalysts discharged from the outlet of the dense bed reactor can be introduced into the stripper via a specific catalyst transporting channel, so as to maintain higher activity and temperature of the catalyst in the dense bed reactor and be advantageous to deeper cracking of the intermediate products in the dense bed reactor so as to produce more light olefins, particularly propylene. | 2009-05-07 |
20090117018 | Process for the Separation and Purification of Hafnium and Zirconium - A process for the separation and purification of hafnium and zirconium. | 2009-05-07 |
20090117019 | REDUCING MERCURY EMISSIONS FROM THE BURNING OF COAL - Processes and compositions are provided for decreasing emissions of mercury upon combustion of fuels such as coal. Various sorbent compositions are provided that contain components that reduce the level of mercury and/or sulfur emitted into the atmosphere upon burning of coal. In various embodiments, the sorbent compositions are added directly to the fuel before combustion; are added partially to the fuel before combustion and partially into the flue gas post combustion zone; or are added completely into the flue gas post combustion zone. In preferred embodiments, the sorbent compositions comprise a source of halogen and preferably a source of calcium. Among the halogens, iodine and bromine are preferred. In various embodiments, inorganic bromides make up a part of the sorbent compositions. | 2009-05-07 |
20090117020 | RAPID MICROWAVE-SOLVOTHERMAL SYNTHESIS AND SURFACE MODIFICATION OF NANOSTRUCTURED PHOSPHO-OLIVINE CATHODES FOR LITHIUM ION BATTERIES - The present invention includes methods, coatings, and a nanostructured phospho-olivine composition Li | 2009-05-07 |
20090117021 | Boron Nitride Nanotubes - Boron nitride nanotubes are prepared by a process which includes:
| 2009-05-07 |
20090117022 | CYCLIC PROCESS FOR WET-CHEMICALLY PRODUCING LITHIUM METAL PHOSPHATES - The invention relates to a method for producing lithium metal phosphates of a formula LiMPO | 2009-05-07 |
20090117023 | SILICON MONOXIDE VAPOR DEPOSITION MATERIAL AND PROCESS FOR PRODUCING THE SAME - In a powder-sintered type silicon monoxide based evaporating material which is used to form an evaporated film of silicon monoxide, the generation of splash is restrained. Material strength that can resist against the use of the material is ensured. In order to realize these, a starting powder made of precipitating SiO is sintered at 700 to 1000° C. to form an evaporating material. The precipitation of Si is restrained in the step of the sintering. In the measurement thereof by XRD, the peak strength P | 2009-05-07 |
20090117024 | Process for the Production of Hydrogen with Co-Production and Capture of Carbon Dioxide - A process for the production of hydrogen with the co-production and capture of carbon dioxide, wherein the process comprises steam methane reforming a hydrocarbon feedstock in the presence of a fuel and a combustion sustaining medium using (i) a steam methane reformer unit that comprises a steam methane reformer (SMR), and (ii) a water gas shift unit, so as to result in the production of a reformed gas stream comprising hydrogen and carbon dioxide, and a combustion products stream. The process comprises the steps of: (a) separating and removing most or all of the hydrogen from the reformed gas stream; and then (b) recovering most or all of the carbon dioxide as a separate by-product stream by condensation of liquid carbon dioxide from the gas stream; and then (c) recycling the remaining gases from the gas stream by mixing these gases with the SMR feed stream. The fuel used is principally hydrogen, for example the fuel may contain 95 mol % or more hydrogen when measured on a dry basis. Greater than 85%, typically greater than 99%, of the carbon contained in the feed stream to the process is recovered and exported as carbon dioxide. | 2009-05-07 |
20090117025 | Injector Apparatus and Methods for Production of Nanostructures - An apparatus for use with a reactor for synthesis of nanostructures is provided. The apparatus includes a chamber having one end in fluid communication with the reactor and defining a pathway along which a fluid mixture for the synthesis of nanostructures can be injected into the reactor. The apparatus also has a tube in fluid communication with an opposite of the chamber to impart a venturi effect in order to generate from the fluid mixture small droplets prior to introducing the fluid mixture into the chamber. A heating zone is situated downstream from the tube to provide a temperature range sufficient to permit the formation, from components within the fluid mixture, of catalyst particles upon which nanostructures can be generated. A mechanism is further provided at a distal end of the chamber to minimize turbulent flow as the fluid mixture exits the chamber, and to impart a substantially laminar flow thereto. A method for synthesis of nanostructures is also provided. | 2009-05-07 |
20090117026 | Method for manufacturing carbon nano-tube - A method for manufacturing a carbon nano-tube by a chemical vapor deposition includes: introducing a carbon source gas into a reaction chamber; growing the carbon nano-tube by using a catalyser; and maintaining a pressure of the carbon source gas in the reaction chamber in a range between 1.0 Torr and 2.0 Torr so that the carbon nano-tube is formed. Since the pressure is maintained in a range between 1.0 Torr and 2.0 Torr, the catalyser is not caulked. Thus, the carbon nano-tube is stably formed. | 2009-05-07 |
20090117027 | Method of Carrying Out a Reaction in a Microreaction Chamber - Disclosed is a method for carrying out a reaction in a microreaction chamber. Nanoparticles which have been advantageously subjected to specific reactions in the microreaction chamber are used for carrying out the reaction. The obtained reaction product, which is preferably also provided in the form of nanoparticles. can then be removed from the microreaction chamber. Advantageously, the ongoing reaction can be specifically influenced by using the microreaction chamber. Both endothermic and exothermic reactions can be carried out with an accurately predictable result by feeding energy in a dosed manner into/out of the reaction chamber. | 2009-05-07 |
20090117028 | RAPID SYNTHESIS OF TITANATE NANOMATERIALS - Provided herein is a hydrothermal process for the rapid synthesis of inorganic nanomaterials (e.g., nanofibers) containing sodium, bismuth, titanium, and oxygen, as well as new compositions made thereby. The process involves heating an aqueous solution or suspension of suitable salts of aforementioned elements at elevated temperature and pressure under constant stirring in a hermetically sealed vessel for a predetermined amount of time (e.g., less than two hours). The powder thus obtained contains nanofibers of rectangular cross-section, with the smallest fibers typically have a cross section of 16 nm×40 nm. Example fibers made by such processes have an aspect ratio exceeding 200. | 2009-05-07 |
20090117029 | Production method of barium titanate - A production method of barium titanate according to the present invention comprises steps of preparing powder mixture of barium carbonate powder and titanium oxide powder and firing the powder mixture. The temperature of the powder mixture is raised to firing temperature at 100° C./minute or more in the range of 400° C. to 700° C.; and maximum temperature at firing is 700° C. or more. The present invention aims at providing a production method, wherein grain growth of barium carbonate particle can be controlled in temperature rising process when producing barium titanate by a solid phase reaction of barium carbonate and titanium oxide; and homogeneous barium titanate powder with small particle size can be produced with excellent energy efficiency. | 2009-05-07 |
20090117030 | Method of Producing High-Purity Hydrogen - For recovering hydrogen with a high recovery from a reformed gas and contributing to downsizing and cost reduction of facilities, a high-purity hydrogen E is obtained by reforming a reformable raw material A through a reforming unit | 2009-05-07 |
20090117031 | Methods for Treating Glioma - The present disclosure provides for method of treatment and/or prevention of disease states that require cystine for maintenance or progression of the disease state. In addition, methods for screening and identifying novel therapeutic agents useful in the treatment of such disease states are described. In one embodiment, the disease state is a cancer, such as, but not limited to, glioma. In this embodiment, methods for the treatment and prevention of glioma by inhibiting cystine uptake or decreasing intracellular cystine concentrations are provided. The present disclosure teaches that glioma cells are dependent on system Xc for cystine uptake. Pharmacological inhibition of system Xc causes a rapid depletion of intracellular glutathione, resulting in decreased cell growth. In contrast, non-malignant astrocytes and cortical neurons remain viable in the presence of Xc inhibitors and continue to take up cystine via alternate amino acid transporters. | 2009-05-07 |
20090117032 | Imaging Agents for Early Detection and Monitoring of Cardiovascular Plaque - The present invention relates in part to imaging agents comprised of a targeting moiety and a label, such as a radionuclide or paramagnetic contrast agent, and methods of use thereof. | 2009-05-07 |
20090117033 | INJECTABLE BIODEGRADABLE PARTICLES - According to an aspect of the invention, injectable polymeric particles are provided that contain a copolymer that contains a hydroxy-acid-based repeat unit selected from a mono(hydroxy acid) unit and a poly(hydroxy acid) unit, an alkyl-ether-based repeat unit selected from a mono(alkyl ether) unit and a poly(alkyl ether) unit, and an acid-based repeat unit selected from a unit comprising multiple carboxylic acid groups and a derivative thereof Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. | 2009-05-07 |
20090117034 | Microorganisms for imaging and/or treatment of tumors - Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. | 2009-05-07 |
20090117035 | Temperature-Sensitive Liposomal Formulation - A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the lipid bilayer, compared to that which would occur in the absence of the surface active agent. The surface active agent is present in the lipid bilayer membrane so as to not destabilize the membrane in the gel phase. | 2009-05-07 |
20090117036 | ANTIBODIES AGAINST GPR64 AND USES THEREOF - GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types. | 2009-05-07 |
20090117037 | Methods Of Treatment Using CTLA-4 Antibodies - The present invention provides method of treatment using human sequence antibodies against human CTLA-4 linked to a cytotoxic agent. In particular, methods of treating cancer and autoimmune disease are provided. | 2009-05-07 |
20090117038 | Breast Endothelial Cell Expression Patterns - To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 2009-05-07 |
20090117039 | CHARGED BIODEGRADABLE POLYMERS FOR MEDICAL APPLICATIONS - In accordance with one aspect of the invention, implantable medical devices are provided which include polymeric compositions that comprise at least one type of biodegradable ionic polymer. The at least one type of biodegradable ionic polymer comprises a biodegradable polymer core and one or more ionic end groups. | 2009-05-07 |
20090117040 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases - The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases. | 2009-05-07 |
20090117041 | Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents - Disclosed are certain cycloSalingenyl pyrimidine nucleoside monophosphates comprising positron emitters or gamma-emitting radiohalides, uses thereof for monitoring Alzheimer's disease progression and evaluating response to therapy and process for their preparation. | 2009-05-07 |
20090117042 | Imaging agents and methods of imaging NAALADase or PSMA - The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity. | 2009-05-07 |
20090117043 | Antibodies That Specifically Bind to Neurokinin B - The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially pre-eclampsia, as well as hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to neurokinin B. | 2009-05-07 |
20090117044 | Method for quantifying the uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement - A method for quantifying the uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement is disclosed. In at least one embodiment of the method, the uptake of the radiotracer in the body region of the patient of interest to the positron emission tomography measurement is quantified taking into account at least one permeability information item relating to the permeability of at least one blood vessel of the patient, in particular in the body region of interest. | 2009-05-07 |
20090117045 | Soy or lentil stabilized gold nanoparticles and method for making same - The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from soy or lentil plant material or a reactive extract thereof of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In methods of the invention, an aqueous solution containing gold salts is mixed with soy or lentil plant material or a reactive extract thereof. In preferred embodiment methods of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with soy or lentil plant material or a reactive extract thereof. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a robust coating derived of the soy or lentil plant material or a reactive extract thereof. | 2009-05-07 |
20090117046 | METHODS FOR EVALUATING GENETIC SUSCEPTIBILITY AND THERAPY FOR CHRONIC INFLAMMATORY DISEASES - The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions. | 2009-05-07 |
20090117047 | Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered. | 2009-05-07 |
20090117048 | Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered. | 2009-05-07 |
20090117049 | Light emitting microorganisms and cells for diagnosis and therapy of tumors - Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided are therapeutic methods in which the microorganisms and cells, which can encoded a therapeutic protein, such as a cytotoxic or cytostatic protein, are administered. | 2009-05-07 |
20090117050 | STEM CELL TARGETING OF CANCER, METHODS AND COMPOSITIONS THEREFOR - Disclosed are methods of detecting and treating a cancer such as an ovarian cancer using stem cells. Detection methods include administering a plurality of labeled stem cells to a subject having, or suspected of having, a cancer; and detecting the distribution of the stem cells. In some configurations, the label can be a nanoparticle such as a mono-crystalline iron oxide, which can be detected by magnetic resonance imaging. Treatment methods include administering a plurality of stem cells comprising a therapeutic agent such as an enzyme which activates a prodrug. In some configurations, the stem cells harbor a nucleic acid sequence encoding a cytosine deaminase, the cells express the enzyme, and the treatment further includes administering the prodrug 5-fluorocytosine, which is converted by the cytosine deaminase to the cytotoxic metabolite, 5-fluorouracil (5-FU). | 2009-05-07 |
20090117051 | URIDINE DIETARY SUPPLEMENTATION COMPLIANCE METHODS AND USE THEREOF - This invention relates to determining the compliance of a subject receiving dietary supplementation with uridine or a uridine source. Specifically, the invention relates to the use of MRS for measuring an increase in brain compounds resulting from dietary supplementation with uridine or a uridine source. | 2009-05-07 |
20090117052 | Enhancement agent for high intensity focused ultrasound treatment and method for screening the same - The present invention discloses an enhancement agent for high intensity focused ultrasound (HIFU) treatment, which is administered to a patient before HIFU treatment and can reduce the level of EEF at the target location to be treated with HIFU. EEF is presented by the expression: EEF=ηPt/V (unit: J/mm | 2009-05-07 |
20090117053 | LOCAL DELIVERY OF 5-AMINOLEVULINIC-ACID BASED COMPOUNDS TO TISSUES AND ORGANS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES - In accordance with an aspect of the present invention, a 5-aminolevulinic-acid-based compound (ALA-based compound) is delivered locally to a tissue or organ within a subject's body. In another aspect, a method of diagnosis or treatment is provided which comprises: (a) locally delivering an ALA-based compound to a tissue or organ within a subject's body and (b) illuminating the tissue or organ with light having a wavelength suitable to induce fluorescence of protoporphyrin IX (PPIX). In some embodiments, a local therapeutic agent is delivered to the targeted tissue or organ for treatment. In another aspect, formulations containing the ALA-based compound are provided. | 2009-05-07 |
20090117054 | SUBLINGUAL SPRAY FOR THE TREATMENT OF PAIN - This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies. | 2009-05-07 |
20090117055 | DISINFECTANT HAVING OZONE - Provided is a disinfectant which is not harmful to the human body and has sterilizing power in atmospheric conditions. Liquid paraffin or Vaseline containing ozone is applied on the human body, or medical equipment to be disinfected is dipped therein. Thus, the disinfection of medical equipment is easily and conveniently achieved. When used on the human body, the disinfectant aids in the treatment of wounds because the disinfectant has a disinfection effect and a moisturizing effect. | 2009-05-07 |
20090117056 | Probiotic oral dosage forms - Provided are probiotic compositions that have enhanced stability under various storage conditions. The stability of the probiotic compositions is enhanced through the addition of various agents and excipients. Examples of agents and excipients that may be used to enhance the stability of probiotic compositions include prebiotics, such as the sugar alcohols mannitol, sorbitol, and lactitol, and/or phytonutrients such as oligomeric proanthocyanidins (OPCs). The probiotic compositions may be formulated into oral dosage forms such as tablets, caplets, and capsules, or manufactured as a chewing gum or as a powder formulation that may be dissolved in a liquid such as water, milk, juice, or yogurt. | 2009-05-07 |
20090117057 | Grape Polyphenolics for Platelet and Bacterial Control - Special extracts of grape berries and Gogi berries can be prepared by exposing fruit juices or preparations to an insoluble binding resin which is then extracted with soluble polyvinylpyrollidone. Grape and Goji extracts made in this way can be used to inhibit or control platelet aggregation. Grape extract has exceptional antibacterial properties and can be used to control oral bacteria and to control MRSA (Methicillin-resistant | 2009-05-07 |
20090117058 | Toothpaste composition for tooth whitening - The present invention relates to a toothpaste composition having tooth whitening effect, and more specifically, to a toothpaste composition which contains hydrogen peroxide, as peroxide releasing oxygen free radicals for the whitening effect, and silica with reduced contents of metal ions, to overcome the difficulty in long-term storage due to the release of oxygen free radicals resulting from degradation of peroxide by metal ions released from other components in the composition, and unsatisfactory tooth whitening effect. The toothpaste composition of the present invention does not release oxygen free radicals during storage, and so has excellent preservativeness and sustained tooth whitening effect. | 2009-05-07 |
20090117059 | COMPOSITIONS AND METHODS OF USE THEREOF, FOR THE TREATMENT OF ORAL PAIN, COMPRISING CLOVES OR EXTRACTS THEREOF IN COMBINATION WITH A STEROID - Provided are compositions for delivery to an individual's mouth to provide immediate as well as long-lasting pain relief, particularly after tooth extraction or other dental procedure, which include clove, a clove extract or eugenol, and optionally a steroid and other additives including an antibiotic. Kits and systems for delivery of the composition to provide sustained pain relief are also provided. | 2009-05-07 |
20090117060 | Cosmetic Process for the Treatment of the Skin with Sun-Protection Products and Sun-Protection Products Combination - The invention relates to a cosmetic method, whereby skin is treated with various sun products, and to a sun product combination. The inventive method is characterized by applying, prior to intensive exposure of the skin to UV radiation, a pre-sun product, then a sun product and finally repeatedly applying an after-sun product. The pre-sun product comprises a radical interceptor, the combination caffeine/complex amino acid salt, the combination photolyase/UV endonuclease and an algae extract of Corallina officinalis. The sun product comprises a UV filter combination of UVA and UVB filters having at least 3% by weight of UVA filter. The after-sun product comprises components similar to those used for the pre-sun product, the content of the radical interceptor and the enzyme photolyase being by 50 to 90% by weight lower, the content of the enzyme UV endonuclease being by 50 to 90% by weight higher, and the algae extract being replaced by a cooling plant extract. | 2009-05-07 |
20090117061 | SKIN CARE PRODUCTS CONTAINING MULTIPLE ENHANCERS - The present invention provides a skin care product comprising at least two enhancers and at least one skin care ingredient, wherein the at least two enhancers are selected from cyclodextrin, pentasodium pentetate, phytic acid, potassium citrate, sodium citrate, potassium gluconate and sodium gluconate. | 2009-05-07 |
20090117062 | Novel plant gene and uses thereof - A novel gene isolated from | 2009-05-07 |
20090117063 | Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA) - Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefor; such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and/or differentiation, etc. | 2009-05-07 |
20090117064 | STABLE VITAMIN B6 DERIVATIVE - A compound represented by the following general formula (I) or a salt thereof: | 2009-05-07 |
20090117065 | ANTIPERSPIRANT GEL COMPOSITION - An antiperspirant composition including a continuous oil phase, a disperse aqueous phase, and a residue-masking agent. The continuous oil phase comprises a water-immiscible liquid and a tack-reducing agent. And the disperse aqueous phase comprises one or more polar solvents and an antiperspirant active. | 2009-05-07 |
20090117066 | Antiperspirant or Deodorant Compositions - Incorporation of a polyol humectant in an anhydrous composition containing an astringent aluminium and/or zirconium antiperspirant salt can result in grit formation and hence poor sensory properties unless the polyol is prior contacted with a perfume carrier. A simpler manufacturing process that enables the composition to retain its moisturising properties employs 20 to 90% of a carrier oil plus up to 10% of a liquid, low molecular weight polyethylene glycol as humectant, preferably having an average molecular weight of from 190 to 600, not prior complexed with the antiperspirant salt. | 2009-05-07 |
20090117067 | Hair Product - A fragrant chemical composition for fashioning hair consisting of shea butter, glyceride, triclosan, aloe vera and menthol that combines to aid in the pressing of hair in a well conditioned and healthful manner, as well as to prevent itching typically associated with certain hair fashions such as braids and dreadlocks. The chemical composition protects these hair fashions, as well as hair color, through varying percentages of natural elements and elements known to be healthful. | 2009-05-07 |
20090117068 | COSMETIC COMPOSITIONS - The present invention relates to a solid cosmetic composition which includes a soap and/or a non-soap surfactant, a hair modification active and/or skin enhancing agent, and at least one silicone and/or mineral oil. | 2009-05-07 |
20090117069 | SUBLIMABLE COMPOSITION FOR CONTROLLING ODOR - The invention relates to a sublimable composition comprising cyclododecane and adipic acid and an optional diluent promoting sublimation of the composition. The sublimable composition is provided with a fragrance which is carried into the air by the sublimable composition to ameliorate or otherwise mask objectionable odors, particularly those odors from toilets, urinals and the like. | 2009-05-07 |
20090117070 | Methods and Crosslinked Polymer Compositions for Cartilage Repair - A method of repairing damaged cartilage and soft tissue in a patient is provided using a biocompatible, non-immunogenic composition. The composition comprises a hydrophilic polymer and a plurality of crosslinkable components having reactive functional groups. The composition used in the method may be loaded with biologically active agents for delivery to the damaged tissues. Kits for use in carrying out the method of the invention are also provided. | 2009-05-07 |
20090117071 | Hydrophobically Modified Cationic Polymers And Their Use As Cleaning Aids - A cleaning composition for hard surfaces containing a polymeric compound comprising a main backbone derived from at least the following monomeric components: (I) 20 to 99.9% by weight of at least one cationic monomer according to formula (I) wherein R | 2009-05-07 |
20090117072 | Treatment of periodontal disease - This invention relates to a method of therapeutic or prophylactic treatment of periodontal disease comprising administering to a subject in need thereof epicatechin and/or catechin and/or a polymeric compound of formula A | 2009-05-07 |
20090117073 | USE OF A FUSION PROTEIN TARGETING THE ED-B FIBRONECTIN DOMAIN FOR TREATMENT OF ATHEROSCLEROSIS - The present invention relates to the use of a fusion protein comprising an antibody part which specifically recognises ED-B fibronectin, an effector part and optionally one or more fusion protein linker(s) and/or antibody linker(s), for the manufacturing of medicaments for the treatment and prevention of atherosclerosis | 2009-05-07 |
20090117074 | Sulfonylpyrroles as Histone Deacetylase Inhibitors - The invention relates to compounds of formula (I) | 2009-05-07 |
20090117075 | Temperature Responsive Delivery Systems - There is provided a new aqueous temperature responsive delivery system made with a temperature responsive polymer and a bioadhesive which is intrinsically cationic. This system may also have an effective amount of a treating agent, which may be a medical or cosmetic agent. The bioadhesive, temperature responsive delivery system is useful in delivering moisturizers or pharmaceutically active agents to the user in controlled release manners, through the tissues in a body cavity. | 2009-05-07 |
20090117076 | Methods For Treating Tumor Cells - Methods of treating a disease in a patient are disclosed that include the administration of a targeted therapy in combination with an immunotherapy. Such therapy is useful in the treatment of any disease susceptible to targeted therapy and attack by the immune system. | 2009-05-07 |
20090117077 | POLYETHYLENE GLYCOL-INTERFERON ALPHA CONJUGATE - The present invention relates to three-branched polyethylene glycol-interferon alpha conjugate of general formula (1) wherein polyethylene glycol has an average molecular weight of from 400 to 45,000 daltons, and a pharmaceutical composition comprising the same. The bioactive polyethylene glycol-interferon alpha conjugate of general formula (1) has antiviral and antitumoral activities, improved yield and purity by high reactivity in the reaction, and the effects to increase the half-life in blood remarkably, and to minimize the decreases in biological activity of interferon. | 2009-05-07 |
20090117078 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF - Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) die oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound. | 2009-05-07 |
20090117079 | METHODS AND MATERIALS FOR TREATING OR PREVENTING DISEASES/DISORDERS MEDIATED BY ALCOHOL DEHYDROGENASE - The present disclosure relates generally to methods and materials for treating and/or preventing a disease or disorder in a subject that is mediated by alcohol dehydrogenase by administering to the subject a therapeutically effective amount of one or more agents that prevents and/or inhibits the metabolism of methanol by alcohol dehydrogenase. Methanol metabolism may be reduced/inhibited in a subject by administering to the subject a therapeutically effective amount of ethanol. | 2009-05-07 |
20090117080 | Beta-Galactosidase with Transgalactosylating Activity - The present invention concerns a new β-galactosidase with transgalactosylating activity isolated from | 2009-05-07 |
20090117081 | PARVOVIRUS METHODS AND COMPOSITIONS FOR KILLING NEOPLASTIC CELLS - According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursers, while leaving healthy cells intact. The invention thus comprises a method of killing cancer and other neoplastic and preneoplastic cells by administration of AAV2 virus, viral particles, products or replication incompetent vectors derived there from to said cells, and pharmaceutical compositions comprising the same. | 2009-05-07 |
20090117082 | Reovirus for the Treatment of Cellular Proliferative Disorders - Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated. | 2009-05-07 |
20090117083 | IMMUNOMODULATORY ALKALOIDS - Immunotherapy comprises administration of an alkaloid at a dose sufficient to induce IL-2 production in dendritic cells in a patient. The alkaloid induces the production of IL-2 in dendritic cells. The alkaloids need not be naturally occurring, and may be synthetic analogues or derivatives of naturally occurring counterparts. Such analogues or derivatives are preferably pharmaceutically acceptable analogues, salts, isomers or derivatives as herein defined. However, preferred alkaloids are phytochemicals. Such phytochemicals may be isolated from natural sources or synthesised in vitro. Particularly preferred are alkaloids is selected from piperidine alkaloids; pyrrolin alkaloids; pyrrolidine alkaloids; pyrolizidine alkaloids: indolizidine alkaloids and nortropane alkaloids. | 2009-05-07 |
20090117084 | BACTERIOPHAGE AND PROPHAGE PROTEINS IN CANCER GENE THERAPY - The present invention relates to the use of a polypeptide having a proliferation inhibitory activity or a cell death inducing activity on animal cells. The invention provides further means and methods to use said polypeptide and the corresponding nucleic acids sequence containing the coding regions of said polypeptide. The invention further relates to vectors expressing said polypeptide, to pharmaceutical compositions and therapeutic methods for treating proliferative disorders or diseases like cancer. Last but not least the invention provides a method for a gene therapeutic approach using said polypeptide having a proliferation inhibitory activity or a cell death inducing activity on animal cells. | 2009-05-07 |
20090117085 | MNTF DIFFERENTIATION AND GROWTH OF STEM CELLS - The present invention provides methods for inducing differentiation of an embryonic stem cell into a motor neuron using a motoneuronotrophic factor (MNTF) or its peptide analogues. The present invention further provides a method for isolating a population of stem cell derived motor neurons and a population of cells comprising the differentiated neural cells. Additionally, the present invention is directed to a method of enhancing the survival of the differentiated neural cells in long term cell cultures. Finally, the present invention provides compositions containing MNTF or its peptide analogs for therapeutic use in conjunction with stem cells. | 2009-05-07 |
20090117086 | Preparation of replicating macrophages and use in diagnosis and therapy - Provided are methods for replicating macrophages in vitro and cell culture compositions comprising replicating macrophages. Also provided are methods for preparing replicating Kupffer cells from human liver. Further provided are methods for enhancing or extending immune function in an individual suffering from a deficiency relating to a reduced number of functional macrophages in a tissue or organ by administering a therapeutically effective amount of a replicating macrophages obtained by the methods of the invention. | 2009-05-07 |
20090117087 | METHODS AND COMPOSITIONS FOR PRINTING BIOLOGICALLY COMPATIBLE NANOTUBE COMPOSITES OF AUTOLOGOUS TISSUE - A method of carrying out an autologous tissue implant in a subject in need thereof is carried out by: (a) forming an autologous tissue implant from autologous cells collected from a subject (e.g., by ink-jet printing, the autologous cells and the scaffold, separately or together), and then (b) implanting the autologous tissue implant in said subject. | 2009-05-07 |
20090117088 | CELLULAR INTERVENTION TO TREAT DAMAGED MYOCARDIUM - A system and method for treating damage myocardial tissue includes delivering replacement cells to the myocardium of a patient and electrically stimulating the spinal column of the patient to affect a cellular environment within the myocardium. | 2009-05-07 |
20090117089 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS - This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 2009-05-07 |
20090117090 | INHIBITION OF GLYCOGEN SYNTHASE KINASE 3 BETA IN ARTERIAL REPAIR AND STENT RE-ENDOTHELIALIZATION - A device having a kinase inhibitor for treating or preventing vascular disease in a subject and a method of treating a subject therewith, is disclosed. The device can be a stent coated with the kinase inhibitor. The kinase inhibitor can be a glycogen synthase kinase (GSK) inhibitor, such as a GSK-3β inhibitor. Coronary artery disease and ischemic heart disease can be treated. | 2009-05-07 |
20090117091 | Methods for treating pompe disease - The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner. | 2009-05-07 |